Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The following table summarizes their recent ...
NeoGenomics (NEO) has quietly strung together a solid rebound, with shares up roughly 44% over the past 3 months and about 16% this month, drawing fresh attention after a tough year. See our latest ...
Long-Range Plan reflects 12-13% revenue growth annually Presentation and webcast at 43 rd Annual J.P. Morgan Healthcare Conference today, Wednesday, January 15, at 1:30 p.m. PT / 4:30 p.m. ET “We ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback